Business
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services,
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting taking place June 2-6 in Chicago, Illinois.\"Together with our collaborators from leading medical institutions, NeoGenomics is proud to present extensive data at this year's ASCO Annual Meeting,\" said Vishal Sikri, President of Advanced Diagnostics at NeoGenomics. \"These presentations highlight the utility of the RaDaR assay for molecular residual disease (MRD) and the transformational impact it can have on improving a cancer patient's outcome.\"Posters showcasing NeoGenomics' MRD and recurrence monitoring efforts include a Trials in Progress presentation for what is believed to be a first-in-its-kind MRD-directed interventional study in high risk, early stage HER2+ breast cancer, \"KAN-HER2 MRD\" (NCT05388149). The RaDaR assay is being used to identify patients with MRD eligible for this Phase 2 trial, and NeoGenomics will process samples and provide test results throughout the trial.\"We are excited to be working with NeoGenomics and our other partners, with the support of the Ontario Institute of Cancer Research, to evaluate novel individualized adjuvant therapy for patients with HER2+ breast cancer,\" said Dr. David Cescon, Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre. \"We believe that identifying the specific individuals at greatest risk for recurrence could represent a paradigm-changing path towards the most effective development and delivery of therapies with curative potential. Prospective use of the RaDaR assay will allow us to both identify eligible participants with MRD and evaluate changes in ctDNA as a surrogate of treatment response in KAN-HER2.\"Also being presented are findings from five studies using the RaDaR MRD assay in lung, breast, and head and neck cancers, as well as the InVisionFirst®-Lung liquid biopsy in metastatic non-small cell lung cancer.Details of NeoGenomics' poster presentations at the 2023 ASCO Annual Meeting are outlined below, and further details can be found in the ASCO Meeting Library.Friday, June 2, 2...